Status:
RECRUITING
Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD
Lead Sponsor:
Peking University Cancer Hospital & Institute
Collaborating Sponsors:
Tianjin Chest Hospital
Peking University First Hospital
Conditions:
NSCLC
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
It is a prospective, multicenter, randomized controlled trial to investigate the predictive value of MRD on adjuvant therapy. Stage IA2-II resected NSCLC patients will undergo two-round MRD tests afte...
Eligibility Criteria
Inclusion
- Stage IA2-II non-small cell cancer patients who after complete resection.
- Two-round MRD tests confirm landmark undetectable MRD
- Expected survival ≥24 months
- ECOG PS 0-1
- Willing to accept MRD monitoring every 3 months for a total of 2 years after surgery
Exclusion
- Patients who had previously undergone radiotherapy or chemotherapy or any other anti-tumor therapy
- Patients with a history of other malignancies in the past 5 years
- Any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.) or other conditions that investigators considered would limit the ability of the patient to participate in the study
Key Trial Info
Start Date :
April 6 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
286 Patients enrolled
Trial Details
Trial ID
NCT06924710
Start Date
April 6 2025
End Date
December 31 2029
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China, 100142